Table 1 Overview of patient- and tumour characteristics per patient. CR= Complete response; N=No; NA= Not available; PD= Progressive disease; PR= Partial response; SD= Stable disease; Y=Yes

PatientID	Sex	Tumor stage	Tumor location	Lynch Syndrome Status	No cycles Pembrolizumab	Other systemic treatment	Radiological response	Tumor resected	Pathological response	Additional treatment after Pembrolizumab	Death
1	Female	cT4bN1M1	Colon ascendens	Yes	9		PR	Y	ypT0N0		N
2	Female	cT4aN2aM	Colon ascendens	Yes	34		PR	Y	ypT0N0		N
3	Male	cT4N0M0	Flex. Li	Yes	7		NA	N			Y
4	Male	cT4N1Mx	sigmoid	Yes	19		CR	N			N
5	Female	cT4aN2b	rectum	No	3		PD	N		Radiotherapy	N
6	Male	cT3cN1 M	Rectum	No	9		PR	Y	ypCR		N
7	Male	cT4bN2bM	Rectum	No	12		CR	N			N
8	Male	cT3N1M1	Rectum	No	10		CR	N		Capox	Y
9	Male		Duodenum	Unknown	3		PD	N			Y
10	Female		Jejunum	Unknown	6	Nivolumab	PR	N		Nivolumab	N
11	Female	T4N + M0	Colorectal	No	6		CR	Y	ypT0N1c		N
12	Male		Colorectal	No	6		SD	Y		Folfoxiri-B	N
13	Female		Duodenum	No	2		PR	N			N
14	Female	T4N + M0	Colorect	yes	2		NA	N			Y
15	Female	cT4NxMx	Duodenum	no	10	Nivolumab	PR	N			N
16	Female	T4	Coecumca	no	9		PR	Y	ypT0N0		N
17	Female	T3-4N2M0	Colorect	Yes	6		PR	Y	ypT3N0.		N
18	Female	T4N1M0	Colorect	No	8		PR	Y	ypT0N0.		N

Quick links

Search